Get the Stockscreener App
127.53
3.65%
4.49
Pre-market:
127.61
0.08
+0.06%
Abivax Adr stock is traded at $127.53, with a volume of 4.26M.
It is up +3.65% in the last 24 hours and up +20.18% over the past month.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
See More
Previous Close:
$123.04
Open:
$134.79
24h Volume:
4.26M
Relative Volume:
3.49
Market Cap:
$9.94B
Revenue:
-
Net Income/Loss:
$-159.39M
P/E Ratio:
-36.02
EPS:
-3.5401
Net Cash Flow:
$-105.22M
1W Performance:
+14.96%
1M Performance:
+20.18%
6M Performance:
+1,520%
1Y Performance:
+1,386%
1-Day Range:
$126.14
$138.49
1-Week Range:
$107.06
$138.49
52-Week Range:
$4.77
$138.49
Abivax Adr Stock (ABVX) Company Profile
Compare ABVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
127.53 | 9.59B | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-06-25 | Initiated | Wolfe Research | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jul-23-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-20-25 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | Laidlaw | Buy |
| May-20-24 | Initiated | BTIG Research | Buy |
| Apr-29-24 | Initiated | Guggenheim | Buy |
| Apr-29-24 | Initiated | Piper Sandler | Overweight |
| Nov-14-23 | Initiated | Leerink Partners | Outperform |
| Nov-14-23 | Initiated | Morgan Stanley | Equal-Weight |
View All
Abivax Adr Stock (ABVX) Latest News
A Look at Abivax ADR (ABVX) Shares in the Recent Past Indicates Growth - Setenews
What's Happening With French Biotech Abivax Stock On Wednesday? - Benzinga
Stempoint Capital LP Invests $671,000 in Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax SA Sponsored ADR $ABVX Shares Acquired by Kennedy Capital Management LLC - MarketBeat
Abivax SA Sponsored ADR $ABVX Shares Sold by Affinity Asset Advisors LLC - MarketBeat
A3EWCP Stock Price and Chart — LSX:A3EWCP - TradingView
Abivax SA Sponsored ADR $ABVX Shares Bought by Saturn V Capital Management LP - MarketBeat
Quadrature Capital Ltd Acquires Shares of 19,367 Abivax SA Sponsored ADR $ABVX - MarketBeat
Investors in cash trouble should check out Abivax ADR (ABVX) - Setenews
Abivax SA Sponsored ADR Dividends – LS:A3EWCP - TradingView
ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
There is no doubt that Abivax ADR (ABVX) ticks all the boxes. - Setenews
Abivax SA Sponsored ADR (ABVX) Receives a New Rating from Truist Financial - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Rating of “Buy” from Analysts - Defense World
Abivax (NASDAQ:ABVX) Sees Large Volume IncreaseHere's Why - MarketBeat
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025 - ts2.tech
Is Abivax ADR (ABVX) positioned for future growth? - Setenews
Nothing is Better Than Kyivstar Group Ltd (KYIV) stock at the moment - Setenews
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 12-Month HighStill a Buy? - MarketBeat
Abivax (NASDAQ:ABVX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know - MSN
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year? - sharewise.com
A new trading data show Abivax ADR (ABVX) is showing positive returns. - Setenews
Akebia Therapeutics (AKBA) Receives a Buy from BTIG - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 52-Week HighShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR) - The Globe and Mail
Get in on Abivax ADR’s (ABVX) buy-in window today! - Setenews
Wall Street analysts’ outlook for Zevia PBC (ZVIA) - Setenews
Positive Outlook for Abivax SA: Obefazimod’s Potential in Crohn’s Disease Drives Buy Rating - TipRanks
What is Abivax ADR (ABVX) Stock Return on Shareholders’ Capital? - Setenews
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Decrease in Short Interest - MarketBeat
Leerink Partnrs Analysts Raise Earnings Estimates for Abivax - Defense World
Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Abivax Shares Surge After Strong Phase 3 Results in Ulcerative Colitis Study - MSN
Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease - Investor's Business Daily
FY2025 EPS Estimates for Abivax Boosted by Lifesci Capital - Defense World
Abivax SA Reports Financial Results and Strategic Advances - MSN
Abivax Reports Increased Losses but Secures Major Funding in H1 2025 - msn.com
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 42.1% in August - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Increase in Short Interest - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $95.14 Consensus PT from Brokerages - MarketBeat
Abivax (NASDAQ:ABVX) Shares Gap Down – What’s Next? - Defense World
Octagon Capital Advisors LP Makes New $7.69 Million Investment in Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Down 38.0% in August - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Buy” by Brokerages - Defense World
Abivax Adr Stock (ABVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):